Phosducin regulates G␤␥-stimulated signaling by binding to G␤␥ subunits of heterotrimeric G-proteins. Control of phosducin activity by phosphorylation is well established. However, little is known about other mechanisms that may control phosducin activity. Here we report that phosducin is regulated at the posttranslational level by modification with the small ubiquitin-related modifier, SUMO. We demonstrate modification with SUMO for phosducin in vitro expressed in cells and for native phosducin purified from retina and the heart. A consensus motif for SUMOylation was identified in phosducin at amino acid positions 32-35. Mutation of the conserved lysine 33 to arginine in this motif abolished SUMOylation of phosducin, indicating that SUMO is attached to lysine 33 of phosducin. In transfected cells the steady-state levels of the K33R mutant protein were much lower compared with wildtype phosducin. The investigation of the stability of wild-type phosducin and of phosducin K33R showed a decreased protein stability of the SUMOylation-deficient mutant. The decreased protein stability correlated with increased ubiquitinylation of the SUMOylation-deficient mutant. These findings indicate that SUMOylation protects phosducin from proteasomal degradation. SUMOylation of phosducin decreased its ability to bind G␤␥. PhlP, a closely related member of the phosducin family, was not a target for SUMOylation, but its SUMOylation can be achieved by a single amino acid insertion in the conserved N terminus of PhlP. Together, these findings show that phosducin is a previously unrecognized target of SUMO modification and that SUMOylation controls phosducin stability in cells as well as its functional properties.
Phosducin (Phd)
2 is a regulator of G-protein-coupled signal transduction. The 33-kDa cytosolic protein is found in high concentrations in pineal gland and retina (1, 2) and binds the ␤␥ subunits of heterotrimeric G-proteins (G␤␥) with high affinity. This event leads to neutralization of active G␤␥, effectively impeding G␤␥-mediated signal transduction (3) . Although high protein levels of Phd occur in the retina and the pineal gland, Phd is ubiquitously expressed in many other organs (4) . In addition to Phd, a group of proteins structurally and functionally related to Phd has been identified in several tissues (5, 6) . Among these a long and a short splice variant of the phosducin-like protein (PhlP L and PhlP S ) have been described (6 -8) . Phd and Phd-related proteins show a wide evolutionary distribution and form a highly conserved family of G␤␥-regulating proteins.
Most studies of Phd focused on retinal photoreceptor cells where Phd is thought to inhibit signal transmission from light-activated photoreceptor rhodopsin via transducin, thereby playing a role in dark/light adaptation of the retina (9, 10) . This process requires a tight control of protein interaction and accessibility (11) , necessitating additional regulatory mechanisms besides translational control. One such set of mechanisms is phosphorylation of Phd by different kinases (3, (12) (13) (14) (15) . However, physiological data on the effects of Phd in the retina suggest that further adaptive mechanisms exist that control Phd activity and availability at the posttranslational level (16, 17) .
Many pathways are known that regulate the stability and accessibility of proteins. The most important one is the modification of proteins by ubiquitin leading to increased proteasomal degradation. Phd as well as the PhlP proteins have been shown to interact with the proteasomal subunit SUG1 (16, 18) , and this observation suggests that Phd may be regulated by posttranslational modification.
More recently, a family of proteins closely related to ubiquitin has been discovered. SUMO (small ubiquitin-related modifier) is the best characterized member of this group of ubiquitin-related proteins. Four different subtypes have been identified in mammals that are ϳ18% identical in sequence to ubiquitin (19 -24) . Enzymes involved in SUMO conjugation (SUMOylation) resemble those of ubiquitin conjugation (25) (26) (27) . The SUMO-activating enzyme E1 consists of a heterodimer of the Aos1/SAE1 and Uba2/SAE2 proteins that together constitute the equivalent of the ubiquitin-activating enzyme Uba1 (26) . The only known E2-conjugating enzyme of SUMO is UBC9 (25, 27) . More recent studies revealed three different groups of proteins that act as E3 ligases for SUMO modification in mammalian cells (28 -34) . Moreover, several proteases are known to specifically cleave the isopeptide bonds between SUMO and target proteins (35, 36) , thereby providing a dynamic SUMOylation-deSUMOylation process. Interestingly, these isopeptidases show differences in subcellular distribution, suggesting a spatially controlled regulation of the SUMO modification process (37) .
Despite the steadily growing number of targets of SUMOylation, little is known about the function and regulation of SUMOylation. Whereas ubiquitin primarily mediates protein degradation, SUMOylation appears to be involved in the regulation of diverse protein functions by changing protein-protein interactions and subcellular localization as well as protein stabilization by antagonizing ubiquitinylation (38, 39) .
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G-protein-coupled signal transduction by regulating the stability and functional properties of Phd and could point out additional, still unknown, functions of Phd.
MATERIALS AND METHODS
Plasmid Construction-Wild-type cDNAs encoding Phd and UBC9 were subcloned into the eukaryotic expression vector pcDNA3 after PCR amplification using the sense primer TCCCTCTAGAAGCTTAT-GGAAAAAGCAAAAAGCCAAAGT and the antisense primer TGC-CTCCCCCTCGAGTTATTCCATATCCTCTTCCATGTT for Phd, and the sense primer TCCCTCTAGAAGCTTATGTCGGGGATCG-CCCTCAGCAGA and the antisense primer TGCCTCCCCCTCGAG-TTATGAGGGCGCAAACTTCTTGGC for UBC9 as described previously (40, 41) . The Phd mutant Phd K33R was generated by a PCRbased site-directed mutagenesis strategy using the sense primer AGA-AAGTTTAGATTGGAGAGTGAAGATAGT and the antisense primer ACTCTCCAATCTAAACTTTCTCCAATCATT. For bacterial expression Phd and Phd K33R were subcloned into pET3d vector. The PhlP L mutant PhlP L -⌬71 was generated by a PCR-based site-directed mutagenesis strategy using the sense primer CCGCTTCAAGTT-GGAGACAGACAGAG and the antisense primer TGTCTCCAACT-TGAAGCGGCGCCAGT. The introduction of specific mutations was confirmed by sequencing.
The plasmid pcDNA3-FLAG-SUMO-1 was kindly provided by Thomas Stamminger (University of Erlangen, Germany). The plasmid pcDNA3-FLAG-Ub-K48R was kindly provided by Tony Sourisseau (Université de Rennes, France). psG9m-Myc-GAM1 was a kind gift from Susanna Chiocca (European Institute of Oncology, Milan, Italy).
Cell Culture and Transfection-COS 7 and human embryonic kidney 293 (HEK-293) cell lines were maintained in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal calf serum. All tissue culture media were supplemented with 100 units/ml of penicillin and 100 g/ml of streptomycin. For transient transfections, cells were plated on six-well plates at a density of 3 ϫ 10 5 cells/well and cultured for 5-7 h. Transient transfection was carried out by the calcium phosphate coprecipitation procedure for HEK-293 cells or the DEAE-dextran method for COS cells as described elsewhere (42, 43) , using 1-3 g of plasmid DNA/well. Expression of the transfected gene was analyzed 36 h after transfection.
Antibodies-A polyclonal antiserum against Phd was generated by immunizing rabbits with the protein purified from Escherichia coli (3) . Goat polyclonal antiserum against Phd has been described elsewhere (4) . Reactivity of the antibodies with Phd was confirmed by immunoblotting with recombinant and native Phd. For covalent coupling of rabbit anti-Phd antibodies to Affi-Gel 10, protein-A-Sepharose-enriched antibodies were used (1 mg/ml) and coupled to Affi-Gel 10 affinity support (Bio-Rad) according to the manufacturer's instructions. Monoclonal antibody 21C7 directed against SUMO-1 was obtained from Zymed Laboratories. Anti-Myc-coupled Sepharose (9E10) was from Santa Cruz Biotechnology, and anti-Myc antibody (9B11) was from Cell Signaling. Anti-FLAG M2 antibody was purchased from Sigma. Anti-mouse and anti-rabbit peroxidase-conjugated secondary antibodies were obtained from Dianova.
Western Blotting and Immunoaffinity Purification-Cells were washed in phosphate-buffered saline and disrupted in an ice-cold radioimmune precipitation assay buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (w/v) Nonidet P-40, 0.1% SDS, 0.5% (w/v) sodium deoxycholate, 5 mM EDTA) supplemented with a mix of protease inhibitors (10 g/ml of soybean trypsin inhibitor, 30 g/ml of benzamidine, 1 mg/ml of leupeptin), 10 mM iodoacetamide, and 10 mM N-methylmaleylimide. Lysates were cleared by centrifugation at 20,000 ϫ g for 10 min at 4°C and were diluted in SDS-Laemmli buffer and boiled at 95°C for 10 min. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were transferred onto PVDF membranes (Millipore). The blots were incubated with primary antibodies as indicated, and bound antibody was visualized with secondary antibodies and ECL Plus Western blotting detection reagent (Amersham Biosciences) in accordance with the manufacturer's instructions.
For affinity purification (AP), cells were lysed in ice-cold AP lysis buffer (50 mM Tris (pH 7.4), 300 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100). Cardiac myocytes were prepared as described (44) and were lysed in ice-cold AP lysis buffer. Lysates from bovine retinae were prepared as described elsewhere (43) . Lysates were cleared by centrifugation at 20,000 ϫ g for 20 min at 4°C, and the supernatant was incubated with anti-Phd or anti-Myc antibodies covalently coupled to an Affi-Gel matrix for 2 h at 4°C. The Affi-Gel was collected by gentle centrifugation and washed four times in cold lysis buffer containing 0.1% (v/v) Triton X-100. Proteins were eluted with 100 mM sodium citrate (pH 3.0), denatured by addition of SDS-Laemmli buffer, and analyzed by Western blotting.
Metabolic Labeling of Proteins and Immunoprecipitation-Cells were starved for 2 h in 2 ml of methionine/cysteine-free medium (PerkinElmer Life Sciences), metabolically labeled for 30 min with 400 Ci/ml of EXPRE 35 S-protein labeling mix (PerkinElmer Life Sciences) in methionine/cysteine-free medium (pulse), washed free of unbound radioactive amino acids, and incubated in prewarmed complete medium (chase). At the indicated time points, the cells were disrupted in ice-cold AP lysis buffer and immunoprecipitated with anti-Phd antibodies. Proteins were subjected to SDS-PAGE. Labeled proteins were visualized and quantitatively analyzed with a FLA-3000 imaging system (Fuji).
Phosphorylation of Rhodopsin by G-protein-coupled Receptor Kinase 2-
The kinase activity of G-protein-coupled receptor kinase 2 was assessed by phosphorylation of the receptor substrate rhodopsin in a total volume of 50 l of buffer (20 mM HEPES, pH 7.4) containing 20 nM G-protein-coupled receptor kinase 2, 10 nM G␤␥ subunits, 400 nM rhodopsin, 10 mM MgCl 2 , 2 mM EDTA, and 50 M [ 32 P]ATP. Phd or Phd K33R was added as indicated in Fig. 2B . Phosphorylation was initiated by light and proceeded for 20 min at room temperature. After SDS-PAGE, receptor phosphorylation was assessed by autoradiography. Rhodopsin-enriched membranes were prepared from dark-adapted bovine retinae by sucrose gradient centrifugation (43) .
In Vitro SUMOylation-In vitro SUMOylation of Phd was performed with the SUMOylation control kit from ImmunoKontact (Wiesbaden, Germany) according to the manufacturer's instructions. Briefly, 500 pg of recombinant Phd or Phd K33R expressed and purified from E. coli were incubated with 150 ng of recombinant SAE2/SAE1, 1 g of SUMO-1, and 1 g of UBC9 in reaction buffer (20 mM Hepes (pH 7.5), 5 mM MgCl 2 , 2 mM ATP) for 60 min at 37°C. Subsequently, the reaction products were separated on SDS-PAGE and assayed in anti-Phd Western blot.
G␤␥ Binding Assays-G␤␥ subunits were purified from bovine brain as described (45), and 2.5 mg of protein were covalently bound to 1 ml of Affi-Gel 15 (Bio-Rad) according to the manufacturer's instructions. As a control, Tris-deactivated Affi-Gel 15 was used. For G␤␥ binding assays, 40 g of retinal lysate were incubated with 70 l of beads for 12 h at 4°C in binding buffer (150 mM NaCl, 100 mM Hepes (pH 7.4)). After binding, the retinal lysate was retrieved (flow-through), beads were washed five times in cold lysis buffer containing 0.1% (v/v) Triton X-100, and bound proteins were eluted with SDS-Laemmli buffer (eluate). Equivalent pro-tein amounts of retinal lysate, flow-through, and eluate were analyzed by Western blotting.
RESULTS

Retinal Phd Occurs in Two Different
Forms-Phosducin is highly expressed in the retina. Analysis of retinal Phd in Western blots showed two immunoreactive bands of 33 and 47 kDa (Fig. 1A , "R"). Although the 33-kDa form corresponds to the expected size of Phd, which is similar to that of recombinant Phd expressed in E. coli (Fig. 1A , "E"), the 47-kDa band is a previously unrecognized form of Phd. Both forms of Phd were detectable with two independent antibody species derived from rabbit ( A difference of ϳ15 kDa between the calculated and the apparent molecular mass of a given protein expressed in mammalian cells or tissue was previously found as characteristic for the attachment of a single molecule of SUMO (19, 20, 38, 39, 46 -48) . Thus, we asked whether the 47-kDa form of Phd might constitute the SUMOylated form of this protein. Phd from bovine retina was purified by immunoaffinity purification with anti-Phd antibodies. Bound proteins were eluted and analyzed by Western blot detection. Anti-Phd antibodies reacted with the 33-and 47-kDa bands (Fig. 1B, left panel) . In contrast, an anti-SUMO-1 antibody revealed the 47-kDa band of the anti-Phd blot (right panel), indicating that the high molecular mass protein is indeed SUMOylated Phd. Besides retina, Phd is expressed in many different tissues. Thus, we asked whether SUMOylation of Phd is restricted to the retina only or whether this modification of Phd is also present in other organs such as the heart. Therefore, we prepared cardiac myocytes from rat heart and performed a Western blot analysis with anti-Phd antibodies. Prominent bands of 33 kDa were visible in cardiac myocytes that corresponded to the 33-kDa form(s) of Phd in the retina (microheterogenicity of the 33-kDa band in cardiac myocytes is apparently due to a different phosphorylation state of Phd (data not shown)). Moreover, a 47-kDa band was detectable in the cardiac myocyte lysate, which was of the same apparent molecular mass as the 47-kDa band of SUMOylated Phd in the retina (Fig. 1C, left panel) . To show that the 47-kDa Phd immunoreactive band in cardiac myocytes is indeed SUMOylated Phd, we affinity purified Phd from retinal or cardiac myocyte lysates with anti-Phd antibodies. The eluted proteins were tested against SUMO-1 in Western blots, giving rise to a prominent signal of 47 kDa in the retina. In the cardiac myocytes a faint but distinct signal of the same apparent size was detectable with anti-SUMO antibody (Fig. 1C, right panel) . Taken together, our experiments indicate that Phd is SUMOylated in vivo in different native tissues.
Phd Is SUMOylated at Lysine 33-Analysis of the primary structure of Phd revealed the amino acid sequence FKLE at positions 32-35, which is homologous to the minimal consensus sequence KXE (where is a hydrophobic amino acid and X is any amino acid) previously established as the SUMO attachment site in several other proteins (49) (Fig. 2A) . To investigate whether lysine 33 might indeed serve as an acceptor for SUMO conjugation, we generated a Phd mutant replacing lysine 33 by arginine (Phd K33R ). To exclude that the K33R mutation changed the biological properties of Phd, the ability of Phd and Phd K33R to bind to G␤␥ subunits of heterotrimeric G-proteins was compared. Both wild-type Phd and Phd K33R were purified from E. coli and were tested for the inhibition of G␤␥-dependent G-protein-coupled receptor kinase 2 phosphorylation of rhodopsin. Phd K33R showed G␤␥ inhibitory capabilities equal to wild-type Phd, indicated by a progressive inhibition of rhodopsin phosphorylation signal with increasing Phd or Phd K33R concentrations (IC 50 : Phd, 14.7 Ϯ 1.3 nM and Phd K33R , 17.8 Ϯ 1.2 nM; Fig. 2B ). This suggests the full functionality of the mutant. To prove our assumption that Lys-33 is the SUMO-acceptor lysine in Phd, we performed an in vitro SUMOylation assay with recombinant Phd and Phd K33R . Although under control conditions Phd and Phd K33R were only detectable as a single form of 33 kDa (Fig. 2C, lanes 1 and 2) , upon addition of SUMO-1, E1, and E2 a second form of wild-type Phd of 47 kDa was visible (lane 3) whereas no modification of Phd K33R occurred (lane 4). This indicates that Lys-33 in Phd is the only SUMOylation site of Phd. To further confirm these results in cells, Myc-tagged Phd or Phd K33R were expressed in HEK-293 cells together with UBC9 and FLAG-SUMO-1. Wild-type Phd was modified with SUMO-1 upon coexpression with SUMO-1 and UBC9 (Fig. 2D, lane 3 versus lane 1) , giving rise to a band of similar apparent molecular mass as the 47-kDa A, bovine retinae were disrupted in 20% sucrose as described. 30 g of retinal lysate (R) and 10 ng of recombinant His 6 -tagged Phd purified from E. coli (E) were subjected to SDS-PAGE, and proteins were transferred on PVDF membranes. Western blot analysis was performed with either anti-Phd antibodies derived from rabbit serum (left panel) or anti-Phd antibodies derived from goat serum (right panel). B, 40 mg of retinal lysate were subjected to immunoaffinity purification (AP) with anti-Phd antibodies bound to an Affi-Gel matrix. Bound proteins were eluted with 100 mM sodium citrate (pH 3.0), and eluates were collected. Five fractions were subjected to SDS-PAGE, and proteins were transferred on PVDF membranes. Western blot analysis (WB) was performed either with anti-Phd antibodies (left panel) or anti-SUMO-1 antibodies (middle panel). 30 g of retinal lysate before purification (pre) and an equivalent amount of the resin flow-through after the purification (post) are given as control (right panel). C, lysates of bovine retina and rat cardiac myocytes were prepared as described under "Materials and Methods." 3 g of the retinal lysate and 100 g of the cardiac myocyte lysate were separated by SDS-PAGE, transferred on PVDF membranes, and subjected to Western blot detection with anti-Phd antibodies (left panel). 1 mg of total protein of each lysate was subjected to immunoaffinity purification with anti-Phd antibodies covalently attached to an Affi-Gel matrix. Bound proteins were eluted with 100 mM sodium citrate (pH 3.0), proteins were separated by SDS-PAGE, and proteins were transferred on PVDF membranes. lanes 2 and 4) . Taken together, these results show that Phd is SUMOylated in vitro and in living cells at lysine 33 and that mutation of lysine 33 to arginine in Phd prevents the SUMOylation of Phd.
A SUMOylation Site in PhlP L Is Generated by Deletion of Glu-71-In contrast to Phd, the amino acid sequence of PhlP L does not contain a KXE motif. The alignment of Phd and PhlP L shows a single amino acid insert in PhlP L within the region homologous to the SUMOylation motif of Phd (Fig. 3A) . We therefore searched for differences regarding SUMOylation between the two members of the Phd family. HEK-293 cells were transfected with plasmids encoding for Myc-tagged versions of Phd, PhlP L , or PhlP L -⌬71. PhlP L -⌬71 is a mutant of PhlP L that lacks glutamine 71, thereby reconstituting the SUMOylation motif FKLE present in Phd (Fig. 3A) . Myc-tagged proteins were expressed in HEK cells in the absence or presence of SUMO-1 and UBC9 and were affinity purified with anti-Myc antibodies. Western blot analysis of the enriched Phd and PhlP proteins revealed that the apparent molecular mass of PhlP L was 44 kDa both in the absence or presence of SUMO-1 and UBC9 (Fig. 3B, lane 2 (Fig. 4A ). This observation was made over a wide range of plasmid-DNA concentrations (Fig. 4B) , suggesting that the steady-state K33R showed a reduction of 40% in the same time interval (Fig. 5, A and B) . This finding indicated that the SUMOylation-deficient mutant of Phd had a decreased half-life compared with wild-type Phd, an observation that could explain the reduced steady-state levels of Phd K33R . To show the effect of SUMOylation on Phd protein stability directly, we assessed the stability of Phd under conditions with and without SUMOylation. Therefore, HEK-293 cells were cotransfected with Phd and proteins of the SUMOylation cascade.
In addition, one set of cells was cotransfected with GAM1. This adenoviral protein has been shown to be an effective inhibitor of SUMOylation in vivo and prevented SUMOylation of Phd in transfected cells (50) . 36 h after transfection, the cells were treated with 100 g/ml of cycloheximide (CHX) for the indicated times to block protein synthesis. This allowed us to monitor the steady-state levels of proteins that had been expressed before CHX treatment. After CHX treatment, cells were lysed and proteins were subjected to Western blot analysis with antiPhd antibodies. Under control conditions a significant amount of Phd was SUMOylated (Fig. 5C, left panel) , whereas in cells expressing the SUMOylation inhibitor only a faint band of 47-kDa SUMOylated Phd was detectable (right panel). The quantification of the Phd band by densitometry revealed that the levels of Phd did not significantly change after 8 h with intact SUMOylation. In contrast, the amounts of Phd decreased by 75% at 8 h when SUMOylation was inhibited (Fig. 5D) . Together, these experiments show that Phd stability is maintained by SUMOylation, whereas Phd, which cannot be SUMOylated either by deletion of the acceptor lysine or by blockade of the SUMOylation process, is degraded more rapidly.
Increased Ubiquitinylation of the SUMOylation-deficient Phd Mutant-To find out whether the lower steady-state protein levels of the SUMOylation-deficient Phd mutant were accompanied by increased ubiquitinylation and subsequent proteasomal degradation, modification of wild-type Phd and of Phd K33R by ubiquitin was analyzed. We cotransfected HEK-293 cells with plasmids encoding wild-type Phd or Phd K33R together with wild-type ubiquitin. Transfected cells were lysed and subjected to Western blot analysis with anti-Phd antibodies. Cotransfection of ubiquitin did barely alter protein levels of wild-type Phd (Fig. 6A, lane 1 versus lane 3) , whereas cotransfection of ubiquitin decreased the levels of Phd K33R dramatically (lane 2 versus lane 4). Protein levels were controlled by the Western blot detection of c-Src, a protein that is not efficiently subjected to proteasomal degradation under basal conditions (51) . In contrast to Phd K33R , protein levels of c-Src were not altered upon ubiquitin expression (Fig. 6A, middle panel  versus bottom panel) . Thus, expression of ubiquitin specifically decreases protein levels of the SUMOylation-deficient mutant Phd K33R . To confirm that ubiquitinylation of Phd is indeed regulated by SUMOylation, we cotransfected HEK-293 cells with plasmids encoding Myc-tagged wild-type Phd or Phd K33R together with FLAG-Ub K48R . In this ubiquitin mutant, lysine 48, which is required for formation of polyubiquitin chains, is exchanged for arginine, thereby reducing proteasomal degradation and facilitating detection of ubiquitinylated proteins (52) . Transfected cells were lysed, and Phd was enriched by immunoaffinity purification using anti-Myc-coupled Sepharose. Detection of the FLAG epitope of FLAG-Ub K48R using an anti-FLAG antibody in a Western blot of the purified proteins showed increased ubiquitinylation of Phd K33R compared with wild-type Phd, visible as two prominent anti-FLAG immunoreactive forms of Phd of 40 and 48 kDa, corresponding to the mono-and diubiquitinylated forms of Phd (Fig. 6B, upper panel) . To confirm the precipitation of equal amounts of wild-type Phd and Phd K33R , the 33-kDa form of Phd was visualized with anti-Phd antibodies (lower panel). These experiments show that Phd levels are controlled by SUMOylation, which impairs ubiquitin-mediated proteasomal degradation of Phd. If SUMOylation of Phd is prevented in the SUMOylation-deficient mutant Phd K33R , ubiquitinylation is increased, leading to enhanced protein degradation.
SUMOylation Disrupts G␤␥ Binding of Phd-As we showed that SUMOylation of Phd occurs in native tissue we asked whether SUMOylation of Phd might also influence the major physiological function of Phd, i.e. the ability to bind to G␤␥ subunits. To address this question, retinal lysates containing high amounts of SUMOylated and nonSUMOylated forms of Phd were incubated with purified G␤␥ subunits that had been covalently attached to Sepharose beads. The retinal lysates were analyzed in Western blot with anti-Phd antibodies before (input) and after (flow-through) incubation with the G␤␥ subunit-containing matrix. As a control, a deactivated Sepharose matrix was used (Fig. 7A, left panel) . The G␤␥-containing matrix depleted about three times more of the non-SUMOylated 33-kDa form of Phd than the control matrix without G␤␥ subunits (Fig. 7, A and B, left panels) . In contrast, the SUMOylated 47-kDa form of Phd did not appear to significantly bind to the G␤␥-containing matrix because it was neither depleted in the flow-through (Fig. 7A, left panel) nor eluted from the matrix (right panel). Thus, the SUMOylated form of Phd does not significantly interact with G␤␥ subunits. These findings demonstrate that SUMOylation controls the G␤␥ binding properties of Phd.
DISCUSSION
Here we have shown that Phd is a previously unknown substrate for SUMO-1 modification. First, in addition to the well established 33-kDa form of Phd we detected a 47-kDa form of Phd in bovine retina. Second, we identified the high molecular mass form of Phd as SUMOylated Phd modified with a single molecule of SUMO. Although Phd is expressed ubiquitously, the highest expression levels of Phd are found in the retina or the pineal gland (4) . In line with these observations, we found high levels of unmodified Phd and a minor proportion of SUMOylated Phd in the retina. Using large amounts of protein from cardiac myocytes, we also detected unmodified Phd as well as SUMOylated Phd. These results show that SUMOylated Phd can also be found in other tissues for which expression of Phd has been shown. Therefore, we propose that SUMOylation of Phd is a ubiquitous event.
To identify the lysine residue used for covalent coupling of SUMO, we screened the amino acid sequence of Phd for the short SUMOylation motif KXE (where represents a hydrophobic amino acid), which was previously found in the majority of bona fide SUMOylated proteins (49) . The amino acids [32] [33] [34] [35] in Phd match this pattern, and mutagenesis of lysine 33 completely abolished modification of Phd by SUMO-1 in vitro and in vivo, thus indicating that lysine 33 is the only SUMOylation site in Phd. The Phd-like protein PhlP L shares a high sequence homology with Phd. Although the SUMOylation motif identified in Phd is located in a highly homologous stretch of both proteins, the corresponding sequence of PhlP L contains an additional glutamine at position 71, disrupting the SUMOylation motif of PhlP L . By deleting this amino acid we could introduce SUMOylation to PhlP L , confirming that the general four-letter motif KXE is crucial for the process of SUMOylation. Moreover, these findings show that despite the high sequence homology of Phd and PhlP L these two members of the Phd family display distinct differences. This is in line with the recently described functional differences between Phd and PhlP, because the latter appears to impair G␤␥ function by inhibiting correct G␤␥ folding (53, 54) .
Our study also shows that the loss of the acceptor lysine for SUMOylation results in an increased ubiquitinylation of Phd. This observation supports the concept that there is a close interplay between the two protein modifications. However, the biological consequences of SUMOylation and ubiquitinylation are quite different. Whereas ubiquitin mainly triggers the proteasomal degradation of proteins, SUMO serves several different purposes. For some proteins it has been shown that attachment of SUMO-1 prevents ubiquitinylation and reduces proteasomal degradation of those proteins (46 -48) . Interestingly, the SUMOylation-deficient Phd mutant, Phd K33R , revealed much reduced steady-state levels compared with wild-type Phd. As shown in pulsechase experiments, Phd K33R is subject to rapid degradation whereas wild-type Phd is degraded much more slowly. Additionally, blockade of cellular SUMOylation made wild-type Phd much less stable, with degradation kinetics similar to Phd K33R in pulse-chase experiments. When transfected into HEK-293 as well as COS 7 cells, Phd K33R showed an ϳ50% reduced protein level compared with the wild-type. Accelerating the ubiquitinylation machinery by overexpression of ubiquitin resulted in an even larger instability of Phd K33R . This is consistent with the finding that the SUMOylation-deficient mutant shows high levels of ubiquitinylation, which can be seen upon inhibition of proteasomal degradation by using the Ub K48R mutant. We show that Phd K33R is functional with respect to its main physiological target, G␤␥, suggesting that the K33R mutation has no major impact on the structure of Phd. Because mutation of lysine 33 in Phd resulted in an increased ubiquitinylation of . A, HEK-293 cells were transfected with either wild-type Phd or the SUMOylation-deficient K33R mutant. Equivalent amounts of Phd protein were expressed. Stability of both forms was evaluated in pulse-chase experiments by labeling for 30 min with [ 35 S]methionine/cysteine-containing medium (400 Ci/ml) and a subsequent chase with medium containing non-radioactive methionine and cysteine. At t 0 and t 60 after the chase cells were lysed, and Phd was immunoprecipitated with anti-Phd antibodies. 35 S-labeled Phd was analyzed with a FLA-3000 phosphorimager. B, means of five independent experiments (Ϯ S.E.) are shown. The amount of [
35 S]Phd is given as percent of control (100% at t 0). The statistical significance was determined by an unpaired t test: p Ͻ0.05 for wild-type Phd versus Phd K33R at t 60. C, HEK-293 cells were transfected with Phd, UBC9, FLAG-SUMO 1, PLC␤1, and an inhibitor of SUMOylation (GAM1) or empty vector (control) as indicated. 36 h after transfection, cells were treated with 100 g/ml of cycloheximide (CHX) for the indicated time periods. Cells were lysed, and proteins were separated on SDS-PAGE and transferred on PVDF membranes. Western blot analysis was performed with anti-Phd antibodies. D, Western blots as described in panel C were analyzed by densitometry. The intensity of the Phd band is expressed as percent of the Phd band without CHX treatment (100%). Means of three independent experiments (Ϯ S.E.) are shown.
Phd, we conclude that in Phd SUMO and ubiquitin do not compete for the same lysine residue. We instead propose a mechanism for stabilization of Phd by SUMOylation where SUMO masks the region recognized by the ubiquitin machinery as it has been described for cMyb (47) .
Apart from the increase in the stability of Phd, SUMOylation appears to also alter functional properties of Phd. It is well known that SUMOylation influences the interaction of many target proteins with other proteins and might serve as an adaptor for protein-protein interactions. Interestingly, the SUMOylated lysine 33 in Phd is located in a region that was identified as crucial for the binding of G␤␥ subunits (55) (56) (57) . To address this observation, we performed G␤␥ binding studies with Phd from bovine retina, and we showed that SUMO completely disrupted the binding to G␤␥ subunits. This finding implies that SUMOylation shuts off Phd and subsequently more ␤␥ subunits from activated G-proteins will be available for signaling. Thus, together with phosphorylation, SUMOylation may constitute a posttranslational modification that switches off the function of Phd and thereby might activate G-protein-mediated signal transduction. It should be interesting to compare the dynamics of both modification processes as it has been shown more recently that phosphorylation and dephosphorylation of Phd in the retina take place within a few minutes (15) . In addition, SUMO is known to be attached to some proteins within seconds (58) and high dynamics of modification and cleavage of SUMO is discussed. However, initial experiments showed that light does not alter SUMOylation of Phd, although this process is known to alter the phosphorylation of Phd (data not shown).
Further on, it will be interesting to analyze whether SUMOylation of Phd supplies this protein with yet unidentified functions. Previous studies emphasize that parts of the SUMOylation machinery are associated with the nuclear pore complex that triggers the import of proteins into the nucleus (32) . There is some evidence that Phd occurs in the nucleus, and a role in transcriptional regulation has been proposed (59) . Whether these findings are connected to the SUMO modification of Phd needs to be clarified. The dynamic process of mutually exclusive SUMOylation and ubiquitinylation of Phd, its presence in several tissues, and the effect on its function add a new level of regulation to this protein and may open a door to previously unexpected features of Phd.
